Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

MyMD Pharmaceuticals, Inc. (MYMD)

1.99   -0.1 (-4.78%) 12-02 16:00
Open: 2.05 Pre. Close: 2.09
High: 2.1 Low: 1.95
Volume: 206,800 Market Cap: 79(M)

Technical analysis

as of: 2022-12-02 4:24:44 PM
Overall:       
Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 2.94     One year: 3.35
Support: Support1: 1.95    Support2: 1.62
Resistance: Resistance1: 2.51    Resistance2: 2.86
Pivot: 2.1
Moving Average: MA(5): 2.06     MA(20): 2.15
MA(100): 3.12     MA(250): 3.58
MACD: MACD(12,26): -0.2     Signal(9): -0.2
Stochastic oscillator: %K(14,3): 31.2     %D(3): 32.2
RSI: RSI(14): 39.9
52-week: High: 7.22  Low: 1.87
Average Vol(K): 3-Month: 168 (K)  10-Days: 125 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ MYMD ] has closed above bottom band by 9.0%. Bollinger Bands are 82.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 28 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 2.1 - 2.12 2.12 - 2.13
Low: 1.92 - 1.93 1.93 - 1.94
Close: 1.97 - 1.99 1.99 - 2.01

Company Description

MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the causes of disease. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines; and to delay aging and increase longevity, as well as treat autoimmune diseases and COVID-19-associated depression. It is also developing Supera-CBD, a synthetic derivative of cannabidiol for treating chronic pain, addiction, and epilepsy. The company was founded in 2014 and is headquartered in Baltimore, Maryland.

Headline News

Wed, 23 Nov 2022
MyMD Pharmaceuticals : Managing Phase 1 and Phase 2 Clinical Trials - Marketscreener.com

Fri, 18 Nov 2022
MYMD PHARMACEUTICALS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) - Marketscreener.com

Mon, 14 Nov 2022
MyMD Pharmaceuticals Announces Publication of Phase 1 Data for oral TNF-alpha Inhibitor MYMD-1® in Peer-Reviewed Journal Drug Research - Business Wire

Mon, 26 Sep 2022
Is MyMD Pharmaceuticals Inc (MYMD) Stock a Smart Investment Monday? - InvestorsObserver

Tue, 20 Sep 2022
MyMD Pharmaceuticals® Provides Dosing Update on Phase 2 Multi-Center Clinical Trial of MYMD-1® as a Therapy for Delaying Aging and Extending Healthy Lifespan - Business Wire

Wed, 31 Aug 2022
MyMD Pharmaceuticals Raises $7.4 Million via Sale of Convertible Warrants - citybiz

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 39 (M)
Shares Float 29 (M)
% Held by Insiders 14.2 (%)
% Held by Institutions 10.6 (%)
Shares Short 694 (K)
Shares Short P.Month 673 (K)

Stock Financials

EPS -0.83
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.46
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -37.9
Return on Equity (ttm) -66.5
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 0
Operating Cash Flow -15 (M)
Levered Free Cash Flow -9 (M)

Stock Valuations

PE Ratio -2.41
PEG Ratio 0
Price to Book value 4.32
Price to Sales 0
Price to Cash Flow -5.3

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date 2019-11-24
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.